Comparing advanced and classical immunotherapy for lymphoma treatment
Risk Factor Analysis Study for the Efficacy Comparison Between Advanced Immunochemotherapy and Classical Immunochemotherapy: a Prospective Study for Relapsed/Refractory Lymphoma Patients
Seoul St. Mary's Hospital · NCT06796517
This study is testing whether newer immunotherapy treatments for high-grade B cell lymphoma work better and are safer than traditional methods for adults who have already had treatment that didn't work.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 72 (estimated) |
| Ages | 19 Years to 74 Years |
| Sex | All |
| Sponsor | Seoul St. Mary's Hospital (other) |
| Drugs / interventions | CAR-T |
| Locations | 2 sites (Seoul and 1 other locations) |
| Trial ID | NCT06796517 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of advanced immunochemotherapy, including CAR-T therapy, bispecific antibodies, and antibody-drug conjugates, against classical immunochemotherapy methods such as proteasome inhibitors and monoclonal antibodies in patients with relapsed or refractory high-grade B cell lymphoma. Researchers will analyze survival outcomes and treatment-related safety profiles by comparing patient data from electronic medical records and laboratory findings. The study focuses on adults diagnosed with specific types of lymphoma since January 2015 who have previously undergone immunochemotherapy.
Who should consider this trial
Good fit: Ideal candidates are adults aged 19 to 74 years diagnosed with specific types of high-grade B cell lymphoma after January 2015 who have received prior immunochemotherapy.
Not a fit: Patients who have progressed to acute leukemia, developed solid tumors during treatment, or have active infections may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved survival outcomes for patients with relapsed or refractory high-grade B cell lymphoma.
How similar studies have performed: Other studies have shown promising results with advanced immunotherapy approaches, suggesting potential for success in this area.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 19 to 74 years. * Diagnosed with any of the following after January 2015: diffuse large B cell lymphoma, primary mediastinal large B cell lymphoma, high grade B cell lymphoma, or Burkitt lymphoma * Patients who have received immunochemotherapy as treatment for relapsed/refractory lymphoma Exclusion Criteria: * Patients who have progressed to acute leukemia * Patients who developed solid tumor during treatment * Patients with active infectious status (acute pneumonia, viral infection, active hepatitis B state, or active pulmonary tuberculosis etc.)
Where this trial is running
Seoul and 1 other locations
- Seoul St. Mary Hospital — Seoul, South Korea (RECRUITING)
- Yeoido St. Mary Hospital — Seoul, South Korea (RECRUITING)
Study contacts
- Study coordinator: Sung-Soo Park, MD. PhD.
- Email: sspark@catholic.ac.kr
- Phone: +82-02-2258-6754
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Relapsed/refractory High Grade B Cell Lymphoma, High Grade B-cell Lymphoma, Diffuse Large B Cell Lymphoma Relapsed, Primary Mediastinal Large B-Cell Lymphoma, Burkitt Lymphoma, immunochemotherapy, B cell lymphoma, Relapsed